Expedition Therapeutics raised $115M in Series B funding, led by General Atlantic. The firm will use the capital to advance its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development.
Amount Raised
$115 Million
Round Type
Series B
San FranciscoBiotechnologyHealth CareresearchInvestors
Description
Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing. The round was led by General Atlantic with participation from several investors. The funds will support the advancement of their lead DPP1 inhibitor EXPD-101 and expand their therapy pipeline. Their innovative platform targets neutrophil-driven diseases.
Quick answer
Expedition Therapeutics raised $115 Million in a Series B round, dated August 5, 2026. Investors: Logos Capital, Balyasny Asset Management, Adage Capital Management, Venrock Healthcare Capital Partners, BVF Partners, Sanofi Ventures, RA Capital and Vivo Capital. Expedition Therapeutics is based in San Francisco, California, United States.
- How much did Expedition Therapeutics raise?
- Expedition Therapeutics raised $115 Million in a Series B round on August 5, 2026.
- Who invested in Expedition Therapeutics?
- Logos Capital, Balyasny Asset Management, Adage Capital Management, Venrock Healthcare Capital Partners, BVF Partners, Sanofi Ventures, RA Capital and Vivo Capital are named as investors in this round.
- What does Expedition Therapeutics do?
- Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases.
- Where is Expedition Therapeutics based and how big is it?
- Expedition Therapeutics is based in San Francisco, California, United States. Fundz records about 6 employees.
- Who are the decision-makers at Expedition Therapeutics?
- Fundz holds 2 contacts at Expedition Therapeutics, including the Chief Business Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in research and Biotechnology around the same time
Companies in the same sectors as Expedition Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- BioLineRx Ltd raised $3.8M on August 27, 2026.
- QuantHealth raised $45M (Series B) on August 4, 2026.
- Draig Therapeutics raised $65M (Series B) on July 14, 2026.
- Grail raised $110M (Post-IPO Equity) on June 25, 2026.
- Big Picture Bio raised $2M (Pre-Seed) on September 18, 2026.
- Phosphoenix raised $1.5M (Seed) on September 18, 2026.
Who to call at Expedition Therapeutics, and when
A new round usually means Expedition Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Expedition Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Expedition Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Expedition Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Expedition Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansExpedition Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.